Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.51%
1,098.43
-5.67
-0.51%
—1,104.101,103.921,108.751,097.16——
SIXC
Communications
SIXC
Communications
SIXC
+0.52%
607.30
+3.14
+0.52%
—604.16604.16610.19604.12——
SIXE
Energy
SIXE
Energy
SIXE
-0.37%
1,193.37
-4.44
-0.37%
—1,197.811,200.581,213.071,192.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.15%
1,737.79
-2.62
-0.15%
—1,740.411,739.551,750.271,730.60——
SIXM
Financials
SIXM
Financials
SIXM
+0.52%
637.73
+3.29
+0.52%
—634.44633.13639.67633.01——
SIXR
Staples
SIXR
Staples
SIXR
-0.84%
833.81
-7.09
-0.84%
—840.90839.53841.73833.42——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.54%
213.97
-1.16
-0.54%
—215.13215.13215.85213.89——
SIXT
Technology
SIXT
Technology
SIXT
-0.08%
3,226.04
-2.67
-0.08%
—3,228.713,225.623,227.743,198.95——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.29%
938.59
+2.72
+0.29%
—935.87938.37942.00936.95——
SIXV
Health care
SIXV
Health care
SIXV
-0.36%
1,451.94
-5.18
-0.36%
—1,457.121,452.741,466.881,449.55——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.49%
2,388.15
-11.69
-0.49%
—2,399.842,389.712,394.612,371.22——
Q1 2026 earnings • in 3 days
See details
EBS:NYSE
Emergent Biosolutions Inc
$8.06
+0.37%
(+0.030) 1D
Apr 27, 1:59:17 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
$8.00
High
$8.22
Low
$8.00
Mkt. cap
416.25M
Avg. vol.
748.44K
Volume
222.08K
P/E ratio
8.69
52-wk high
$14.06
52-wk low
$4.71
EPS
$0.93
Beta
2.35
Shares outstanding
51.64M
No. of employees
900
News stories
From sources across the web
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteemergentbiosolutions.com
Next call in 3 days
Thu, Apr 30, 5:00 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-0.25 est.)USD
Revenue / Estimate
-/ (145.00M est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
222.20M
140.90M
231.10M
148.70M
Cost of goods sold
102.80M
80.20M
99.00M
94.00M
Cost of revenue
102.80M
80.20M
99.00M
94.00M
Research and development expenses
-
-
200.00K
-600.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
52.70M
44.00M
28.30M
61.60M
Operating expense
69.00M
60.20M
44.80M
77.30M
Total operating expenses
171.80M
140.40M
143.80M
171.30M
Operating income
50.40M
500.00K
87.30M
-22.60M
Other non operating income
61.80M
-3.70M
-3.70M
-8.10M
EBT including unusual items
92.70M
-16.80M
57.60M
-50.70M
EBT excluding unusual items
97.50M
-17.90M
68.40M
-45.40M
Income tax expense
24.70M
-4.80M
6.40M
3.90M
Effective tax rate
26.64%
28.57%
11.11%
-7.69%
Other operating expenses
-
-
-
-
Net income
68.00M
-12.00M
51.20M
-54.60M
Net profit margin
30.60%
-8.52%
22.15%
-36.72%
Earnings per share
0.71
0.16
1.06
-0.43
Interest and investment income
-
-
-
-
Interest expense
-14.70M
-14.70M
-15.20M
-14.70M
Net interest expenses
-14.70M
-14.70M
-15.20M
-14.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
75.20M
23.50M
110.30M
-100.00K
Gain or loss from assets sale
12.50M
1.00M
2.20M
-11.20M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer